Treatment of Gout Lowers Cardiovascular Risk

BY MARY ELLEN SCHNEIDER
FROM A RHUMATOLOGY MEETING
SPONSORED BY NEW YORK UNIVERSITY

NEW YORK – Evidence is emerging that treating hyperuricemia and gout could help control comorbid cardiovascular disease, according to Dr. Michael H. Pillinger, director of the rheumatology fellowship program at New York University and director of rheumatology at the Manhattan VA Hospital, New York.

Patients with gout tend to have an average of three to four comorbidities, including hypertension, hyperlipidemia, kidney disease, diabetes, and coronary artery disease.

Now there is some limited evidence indicating that lowering uric acid may help to reduce cardiovascular mortality. Dr. Pillinger said at the meeting.

Data presented at last year’s American College of Rheumatology’s annual meeting show that cardiovascular mortality dropped by nearly half among patients taking urate-lowering therapy.

The study, which looked at a database of about 45,000 Taiwanese hyperuricemia patients, also showed that stroke mortality decreased significantly when urate levels were lowered.

And the researchers observed a larger decrease in mortality when patients on the drug actually achieved urate lowering than when they did not.

“This would suggest that there really is a relationship between uric acid and cardiovascular disease,” Dr. Pillinger said.

More research will be needed to know for sure whether lowering uric acid could benefit cardiovascular disease, he said.

And other questions remain as well: For example, is it hyperuricemia or gout that conveys the risk for coronary artery disease? That’s unclear, because most of the current studies have been done comparing only hyperuricemia to cardiac outcomes, he said.

Another Taiwanese database study, published last year, compared patients with hyperuricemia and those with gout vs. control patients.

After adjusting for comorbidities, the researchers concluded that only gout was a risk for cardiovascular mortality (Rheumatology [Oxford] 2010;49:141-6). But Dr. Pillinger said he’s not convinced that the data should have been adjusted, because if gout or hyperuricemia themselves contribute to the comorbidities, then such an adjustment may lead to an underestimation of the impact of uric acid.

To shed more light on the role of gout and hyperuricemia in cardiovascular disease, researchers at NYU have been recruiting patients to a study assessing coronary artery disease in men with hyperuricemia, in those with gout, and in control patients.

Preliminary data from the prospective cohort study indicate that coronary artery disease increases in a stepwise fashion from hyperuricemia to gout, according to Dr. Pillinger.

The researchers are also starting to look at how hyperuricemic patients with lower levels of uric acid (6.9-9.0 mg/dL), compared with those who have higher levels (greater than 9.0 mg/dL).

In that preliminary subanalysis, patients with the highest levels of uric acid had the highest risk for coronary artery disease and MI.

“I think this is beginning to suggest that there’s at least an intermediate risk from having elevated uric acid,” Dr. Pillinger said.

Some studies have also shown that treatment of the inflammation associated with gout could help in cardiovascular disease.

Researchers performed an analysis of nearly 1,300 patients in the New York VA gout cohort.

About half of the patients were on treatment with a non-NSAID, non-narcotic, once-daily analgesic FDA approved for 3 indications across 4 different chronic pain conditions.

Select Important Safety Information About Cymbalta

- Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders.
- Patients of all ages started on therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior.
- Cymbalta is not approved for use in pediatric patients.

See Important Safety Information, including Boxed Warning, and Brief Summary of full Prescribing Information on following pages.
chronic colchicine therapy and half were not taking colchicine.

The cross-sectional study, which was presented at the 2010 ACR annual meeting, found that patients who took colchicine had more than a 50% decrease in MI rates, compared with those who were not on the drug.

Patients also had a lower risk of death and a lower C-reactive protein level, but these results did not achieve statistical significance. “This is very provocative,” Dr. Pillinger said.

A recent study based on data from National Health and Nutrition Examination Survey shows that an estimated 32 million Americans, one-fifth of the U.S. population, have hyperuricemia, which precedes gout.

Gout rates also are increasing in the U.S. NHANES data show a 1.2% increase in gout among U.S. adults, from 2.7% during 1988-1994 to 3.9% during 2007-2008. Men and older adults were the most likely to be at increased risk for gout (RHEUMATOLOGY NEWS, December 2010, p. 12).

Dr. Pillinger said that he had no relevant financial conflicts of interest to report.

VERBATIM

‘The benefits of high-intensity exercise in RA include improvements in aerobic capacity, strength, physical function, and psychosocial well-being.’ Despite these known benefits, many RA patients hesitate to exercise in part because they do not know which activities are safe and in part because it hurts.

Rebecca-Jane Law, p. 9

Cymbalta is indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy.

Available in 20-mg, 30-mg, and 60-mg delayed-release capsules

Cymbalta is indicated for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low back pain (CLBP) and chronic pain due to osteoarthritis.

Cymbalta is indicated for the management of fibromyalgia (FM).